Stryker Corporation $SYK Shares Sold by MBL Wealth LLC

MBL Wealth LLC lowered its position in shares of Stryker Corporation (NYSE:SYK) by 55.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,475 shares of the medical technology company’s stock after selling 1,830 shares during the period. MBL Wealth LLC’s holdings in Stryker were worth $406,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in SYK. Mitchell Mcleod Pugh & Williams Inc. increased its position in Stryker by 1.2% during the first quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 2,678 shares of the medical technology company’s stock worth $880,000 after buying an additional 31 shares during the period. Community Bank & Trust Waco Texas lifted its stake in Stryker by 2.3% in the second quarter. Community Bank & Trust Waco Texas now owns 1,395 shares of the medical technology company’s stock valued at $439,000 after buying an additional 31 shares during the last quarter. Cornerstone Financial Management LLC boosted its holdings in shares of Stryker by 66.0% in the second quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company’s stock valued at $25,000 after acquiring an additional 31 shares during the period. NWF Advisory Services Inc. boosted its holdings in shares of Stryker by 2.3% in the second quarter. NWF Advisory Services Inc. now owns 1,472 shares of the medical technology company’s stock valued at $463,000 after acquiring an additional 33 shares during the period. Finally, Harold Davidson & Associates Inc. boosted its holdings in shares of Stryker by 0.4% in the first quarter. Harold Davidson & Associates Inc. now owns 8,668 shares of the medical technology company’s stock valued at $2,848,000 after acquiring an additional 34 shares during the period. 77.09% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on SYK shares. Piper Sandler lowered their target price on shares of Stryker from $420.00 to $390.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. BTIG Research reduced their price target on shares of Stryker from $358.00 to $316.00 and set a “buy” rating for the company in a research report on Monday, October 12th. BMO Capital Markets reiterated an “outperform” rating and set a $317.00 price target on shares of Stryker in a research note on Wednesday, September 9th. Wolfe Research downgraded shares of Stryker from an “outperform” rating to a “peer perform” rating in a research report on Thursday, August 13th. Finally, Citizens Jmp dropped their price objective on shares of Stryker from $440.00 to $400.00 and set a “market outperform” rating on the stock in a research note on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and a consensus target price of $369.00.

Insider Activity at Stryker

In other Stryker news, insider Dylan Crotty sold 441 shares of the business’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the transaction, the insider directly owned 6,102 shares of the company’s stock, valued at approximately $2,005,178.22. The trade was a 6.74% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Ronda Stryker sold 300,000 shares of the company’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the transaction, the director owned 2,301,375 shares of the company’s stock, valued at approximately $773,031,862.50. The trade was a 11.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 351,267 shares of company stock worth $118,197,701 in the last three months. Insiders own 4.60% of the company’s stock.

Stryker Stock Up 0.2%

Stryker stock opened at $307.65 on Friday. Stryker Corporation has a twelve month low of $267.00 and a twelve month high of $389.33. The stock has a 50 day moving average of $295.23 and a two-hundred day moving average of $311.93. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $118.01 billion, a price-to-earnings ratio of 31.88, a PEG ratio of 1.98 and a beta of 0.78.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%. The company’s revenue was up 9.4% on a year-over-year basis. During the same period last year, the business posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, research analysts expect that Stryker Corporation will post 14.93 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is 36.48%.

Stryker Company Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.